Zadie Davis
Overview
Explore the profile of Zadie Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1751
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland J, Brieghel C, et al.
Hemasphere
. 2025 Jan;
9(1):e70065.
PMID: 39840379
In chronic lymphocytic leukemia, the reliability of next-generation sequencing (NGS) to detect variants ≤10% allelic frequency (low-VAF) is debated. We tested the ability to detect 23 such variants in 41...
2.
Chatzikonstantinou T, Scarfo L, Minga E, Karakatsoulis G, Chamou D, Kotaskova J, et al.
Hemasphere
. 2024 Sep;
8(9):e70004.
PMID: 39290716
No abstract available.
3.
Chatzikonstantinou T, Agathangelidis A, Chatzidimitriou A, Tresoldi C, Davis Z, Giudicelli V, et al.
Leukemia
. 2024 Feb;
38(3):679-680.
PMID: 38366088
No abstract available.
4.
Chatzikonstantinou T, Scarfo L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, et al.
EClinicalMedicine
. 2023 Nov;
65:102307.
PMID: 38033506
Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed...
5.
Mansouri L, Thorvaldsdottir B, Sutton L, Karakatsoulis G, Meggendorfer M, Parker H, et al.
Leukemia
. 2023 Jan;
37(2):504.
PMID: 36635392
No abstract available.
6.
Mansouri L, Thorvaldsdottir B, Sutton L, Karakatsoulis G, Meggendorfer M, Parker H, et al.
Leukemia
. 2022 Dec;
37(2):339-347.
PMID: 36566271
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM)...
7.
Kaufman M, Yan X, Li W, Ghia E, Langerak A, Rassenti L, et al.
Front Oncol
. 2022 Jul;
12:897280.
PMID: 35903706
Patients with CLL with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHVs (U-CLL). Since U-CLL usually express immunoglobulins (IGs) that are more autoreactive and more effectively...
8.
Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, Tresoldi C, Davis Z, Giudicelli V, et al.
Leukemia
. 2022 May;
36(8):1961-1968.
PMID: 35614318
The somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable (IGHV) gene is a critical biomarker for assessing the prognosis of patients with chronic lymphocytic leukemia (CLL). Importantly, independent...
9.
Agathangelidis A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, Karypidou M, Plevova K, et al.
Blood
. 2020 Sep;
137(10):1365-1376.
PMID: 32992344
Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent...
10.
Sutton L, Ljungstrom V, Enjuanes A, Cortese D, Skaftason A, Tausch E, et al.
Haematologica
. 2020 Apr;
106(3):682-691.
PMID: 32273480
Next-generation sequencing (NGS) has transitioned from research to
clinical routine, yet the comparability of different technologies for
mutation profiling remains an open question. We performed a
European multicenter (n=6) evaluation...